Innovax-ND-IBD

RSS

Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)

Authorised
This medicine is authorised for use in the European Union.

Overview

Innovax-ND-IBD is a veterinary vaccine used to protect chickens against Newcastle disease (ND), infectious bursal disease (IBD) and Marek’s disease (MD).

ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.

IBD, also known as Gumboro disease, is a viral infection of chickens associated with death at 3-6 weeks of age. It can make birds more prone to other diseases and can interfere with effective vaccination.

MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs. Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. Birds infected with MD virus can be carriers and shedders of the virus for life.

Innovax-ND-IBD contains a live modified strain of turkey herpesvirus called strain HVP360. The turkey herpesvirus strain HVP360 has been modified so that it will produce proteins from ND virus and IBD virus.

This EPAR was last updated on 19/06/2019

Authorisation details

Product details
Name
Innovax-ND-IBD
Agency product number
EMEA/V/C/004422
Active substance
Cell-associated live recombinant turkey herpesvirus (strain HVP360), expressing the fusion protein of ND virus and the VP2 protein of IBD virus
International non-proprietary name (INN) or common name
Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)
Species
  • Chicken
  • Embryonated chicken eggs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01AD16
Publication details
Marketing-authorisation holder
Intervet International B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
22/08/2017
Contact address

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

27/05/2019 Innovax-ND-IBD - EMEA/V/C/004422 - X/0001

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus

Therapeutic indication

For active immunisation of one-day-old chicks or 18-19 day-old embryonated chicken eggs:

  •  to reduce mortality and clinical signs caused by Newcastle disease (ND) virus,
  • to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (IBD) virus,
  • to reduce mortality, clinical signs and lesions caused by Marek’s disease (MD) virus.

Assessment history

How useful was this page?

Add your rating